Quick ReadPlain-language overview · read this first
This is a company that makes high-end chip manufacturing equipment. It is called AMEC, the domestic leader in etching equipment. Etching means using machines to carve chip circuits layer by layer on wafers with high precision. The report's stance is clear: this is a good company, but the current price is too expensive. The rating is Watch, meaning observe first and do not rush to buy.
It mainly earns money by selling this equipment to chip fabs. The advantage is that once its equipment is installed in a customer's critical production line and has passed mass-production validation, switching to another supplier becomes difficult, which creates strong stickiness. Its growth in recent years has indeed been rapid: in 2025, revenue was about RMB 12.385 billion and profit was about RMB 2.111 billion.
The problem lies in both valuation and cash. The current share price is about 265 yuan, and the company's total market value is about RMB 248.7 billion, which means the price has already built in the smoothest possible story for the next ten years. More importantly, accounting profit looks decent, but the cash that truly lands in the pocket is much thinner. Most of the money is being reinvested in R&D and new factory buildings. In other words, reported earnings look attractive, but freely deployable cash is limited.
According to the report's calculations, a more reasonable buy-in range would be 110 to 150 yuan. Above 250 yuan, the stock is clearly expensive, and the current price sits on the expensive side. The key risk to watch is this: if growth or profitability falls even slightly short of expectations, such a high price could pull back sharply at any time. The report does not tell you to buy or sell. It simply reminds you that this is a good company, but not necessarily a good price today. For conservative investors, waiting is more appropriate than chasing.
The above is only a plain-language explanation of this research report and is not investment advice. The stock market involves risk; enter the market with caution.
LeadAMEC is a leading Chinese high-end semiconductor equipment company, anchored in plasma etch tools and expanding into thin-film deposition, MOCVD, and adjacent platforms. Its long-term case is driven by domestic substitution and advanced-node upgrades, with 2025 revenue of about RMB 12.385 billion and net profit attributable to shareholders of about RMB 2.111 billion, but customer concentration is high and R&D spending is roughly 30% of revenue. Report Rating Watch: a valuable business whose current price already discounts a large share of future success.
Prices in the article are as of publication; see the valuation band above for the live price.
Conclusion First
Initial rating: Watch. If AMEC is viewed as a business to own for more than ten years, rather than as a short-term trading ticker, my judgment is straightforward: it is a highly valuable company, but at the current price it is not a very attractive entry point. The company operates in a market with high barriers, strong long-term demand, and clear tailwinds from domestic substitution and advanced-node upgrades. Yet it currently looks more like a fast-expanding R&D and delivery machine than a mature cash cow that can steadily produce large amounts of distributable cash flow. As of 2026-06-09, Reuters/LSEG delayed quotes showed its share price at about RMB 265.47 per share and market capitalization at about RMB 248.7 billion, corresponding to P/S of about 18.95x, adjusted P/E of about 90.71x, and P/B of about 10.20x. In 2025, the company generated revenue of RMB 12.385 billion, net profit attributable to shareholders of RMB 2.111 billion, and operating cash flow of RMB 2.295 billion, but recurring net profit was only about RMB 1.550 billion. If cash related to capitalized development expenditure is also treated as an unavoidable operating investment, 2025 was closer to a RMB 421 million “strict owner earnings proxy.” This means the current price already embeds a large amount of future success.
Is there a margin of safety at the current price: not obvious. For conservative and balanced investors, I would rather define AMEC as “an excellent company, but currently a good company paired with a high price.” If you are a long-term growth investor who deeply understands semiconductor equipment and is willing to track orders, contract liabilities, R&D capitalization, and the pace of domestic substitution, it deserves a high-priority watchlist position. If you prefer “Buffett-style” simple businesses, stable free cash flow, and clear valuation anchors, AMEC is not comfortable at the moment.
The key uncertainties are mainly threefold. First, can the company ultimately convert high R&D spending and platform expansion into real cash flow at a pace that keeps up with revenue and profit growth? Second, can thin-film, EPI, metrology/inspection, and the planned wet-process/CMP expansion beyond etch truly become second and third growth curves? Third, has the current valuation already discounted most of the smoothest execution path over the next decade?
The table below condenses my judgment into one line:
| Item | Judgment |
|---|---|
| Investment rating | Watch |
| Margin of safety | Not obvious |
| Best suited for | Deep-research, long-term growth investors |
| Less suited for | Conservative, cash-flow-focused investors who prefer simple business models |
| Biggest uncertainty | Cash-flow quality, success of platform expansion, excessive valuation |
Business Understanding and Industry Structure
From a business-model perspective, AMEC is not hard to understand. It essentially sells high-end semiconductor and pan-semiconductor microfabrication equipment, with core products including etch equipment, MOCVD equipment, and thin-film deposition equipment, while also providing related equipment and services. Reuters/LSEG's business description points in the same direction: the company mainly engages in R&D, manufacturing, and sales of semiconductor equipment, with products covering plasma etch, MOCVD, LPCVD, ALD, and others. The company's own public materials show that the most important growth in 2025 still came from etch equipment. Etch equipment sales in 2025 were about RMB 9.832 billion, up about 35.12% year over year; combined LPCVD/ALD sales within thin-film equipment were about RMB 506 million, up about 224.23% year over year. Looking back, etch equipment sales in 2024 were about RMB 7.277 billion, while thin-film equipment had already secured about RMB 476 million of batch orders and generated about RMB 156 million of sales revenue; in 2023, etch equipment sales were about RMB 4.703 billion, and MOCVD equipment sales were about RMB 462 million. This shows that the company is evolving from an “etch leader plus legacy LED/MOCVD business” into a structure centered on etch, with thin-film and other new platforms beginning to scale.
How does it make money? The core is recognizing revenue from equipment sales, supplemented by follow-on demand from spare parts, services, and installed tools. But this is not a consumer-goods business, nor is it SaaS. Its revenue naturally has the features of large projects, long validation cycles, and customer capex cycles, so it will not be as smooth, recurring, or predictable as Coca-Cola. The positive side is that once equipment enters a customer's critical process and passes batch validation, the customer's willingness to switch drops sharply. The less favorable side is that annual delivery, acceptance, and customer expansion schedules can make revenue and cash flow volatile. By the end of 2025, the company had accumulated more than 7,800 reaction chambers in mass production across more than 170 customer production lines in China and overseas, with cumulative etch equipment shipments exceeding 6,800 units. This means the installed base and relationship stickiness are strengthening. At the same time, by the end of 2025 the company had contract liabilities of about RMB 3.04 billion and inventory of about RMB 7.17 billion, which also shows that the order and delivery cycle is not light.
Who are the customers? They are mainly wafer fabs and pan-semiconductor customers, and customer concentration is quite high. In 2025, the top five customers accounted for about 75.00% of annual sales; in 2024, the share was about 70.22%. This is not surprising for an equipment company still in the domestic-substitution and platform-expansion stage, because leading logic, memory, and specialty-process customers are themselves highly concentrated. But it means AMEC's business does not have the dispersed customer structure typical of consumer goods. It looks more like “a few large customers plus high-intensity co-development.” The supplier side is less concentrated: in 2025, the top five suppliers accounted for about 27.01% of annual procurement, versus about 28.40% in 2024. In sales model, the company mainly uses direct sales; in Europe, where customers are more fragmented, it sells through agents. Overall, customer concentration risk is clearly higher than supplier concentration risk.
From an industry perspective, AMEC sits in the semiconductor equipment industry, where structural growth and strong cyclical volatility coexist. SEMI data show that global semiconductor equipment sales/billings reached about USD 135.0 billion in 2025, up 15% year over year; global equipment billings rose 14% year over year in Q1 2026; and at the end of 2024, SEMI forecast that global semiconductor equipment sales would reach USD 139.0 billion in 2026 and USD 156.0 billion in 2027. More importantly, SEMI's view on foundry/logic applications within wafer fab equipment was that 2026 would grow 15% year over year to about USD 69.3 billion, driven by advanced processes, GAA architecture migration, and capacity expansion. In other words, this is not a declining industry. It is a good industry with very strong long-term demand and very large short-term swings.
In terms of competitive structure, the strongest domestic comparable is closer to NAURA Technology Group. Reuters data show that NAURA's product line covers a wider range of core process equipment, including etch, thin-film deposition, thermal processing, wet process, and ion implantation, giving it clearly broader platform width than AMEC. AMEC's strongest long suit is etch, while it is advancing into thin-film, EPI, metrology/inspection, and other areas. China's policy support for domestic equipment substitution is also strengthening. Reuters cited people familiar with the matter in late 2025 as saying that China required newly built semiconductor fabs to use more than 50% domestic equipment. This could be an important external tailwind for AMEC, but it also means part of its growth logic is not purely market-driven and carries some policy dependence. Overall, I rate the industry's attractiveness at 4/5: the runway is long and the ceiling is high, but cycles, technology iterations, and policy variables are all strong.
From a long-term owner's perspective, my answer to “is this a business I can understand?” is: it can be understood at the economic-logic level, but the technical details are not simple. You can understand why it makes money, why it is hard to do, and why customers do not switch easily. But you may not be able to judge like an engineer whether a particular generation of ICP, CCP, LPCVD, or high-selectivity etch route is genuinely leading. For Buffett-style investing, this matters. Therefore, my “business understandability” score is 3/5. If the stock market were closed for five years, I would be willing to hold it only at a lower price and with stronger evidence of cash-flow quality. At the current price, I am not comfortable enough.
Moat and Management
AMEC's moat is not a single brand monopoly. It is an engineering moat formed by the stacking of multiple capabilities. The most important factors are not advertising brand, but process know-how, customer validation cycles, field service capability, installed base, original design, and sustained high R&D investment. By the end of 2025, the company had accumulated more than 7,800 reaction chambers in mass production on customer lines, with cumulative etch equipment shipments exceeding 6,800 units; R&D investment in 2025 was about RMB 3.744 billion, or about 30.23% of revenue; in Q1 2026, R&D expenses still reached RMB 908 million, or 31.14% of revenue. For this type of company, the truly hard-to-replicate part is not “buying a few machine tools and setting up a factory.” It is years of iteration to grind out equipment performance, stability, yield, consistency, and the customer's process window bit by bit. In my view, genuinely replicating AMEC's core capabilities would require at least 5 to more than 10 years of sustained, high-intensity capital and customer co-development. This is an inference, but it rests on solid foundations: very high R&D intensity, long validation cycles, a large installed base, and the pace of advanced-process migration are all visible.
If I judge the ten moat types one by one, my conclusion is closer to “moderately strong, but still under construction.” Brand advantage is medium: the company has already built a fairly strong technical brand in domestic high-end etch, but its global brand power still lags far behind international leaders. Cost advantage is limited: the company relies more on performance, delivery, and local service than on pure low price. Scale advantage is moderately strong: the installed base and number of reaction chambers create a real service and learning curve. Network effects are basically absent. Switching costs are fairly strong, because once customers introduce equipment into critical processes, switching involves revalidation, yield, and production-line risk. Channel advantage is medium: direct sales plus field engineering services are important, but not impossible to replicate. Patent, regulatory, and qualification barriers are fairly strong, although the stronger barrier is really “process qualification.” Data advantage is weak. Corporate culture and operating capability are fairly strong, reflected in original design, sustained high R&D investment, and the pace of new product development. Capital allocation capability is medium: the direction is right, but the return has not yet been fully proven. Taken together, I score AMEC's moat strength at 3.5/5.
Is the moat widening, stable, or narrowing? My answer is: in the core etch business, the moat is probably widening slowly; in the larger proposition of becoming a “platform equipment company,” the moat is still being built. In other words, AMEC is already strong in single-point breakthroughs, but it has not yet grown into an equipment group with platform breadth like NAURA. Reuters' business description of NAURA shows that its product lines cover multiple core steps, including etch, deposition, thermal processing, wet process, and ion implantation. AMEC is advancing toward thin-film, EPI, metrology/inspection, and even wet-process/CMP, but this platform capability has not yet fully converted into stable cash flow and a wider return moat. Put differently, AMEC is “a good company in a good industry,” but it may not yet be “a fully mature great enterprise.”
On management, my basic assessment of the founder and core team is positive. Reuters' list of company leadership shows Gerald Z. Yin as chairman and general manager, and the core executive structure is stable. For years, the company has adhered to a strategy of high R&D, original design, and synchronous iteration with leading customers. The direction is long-term oriented and does not look like a clear pursuit of short-term profit maximization, unlike some equipment companies. The issue is that economic alignment is not especially strong: as of 2025-03-31, Gerald Z. Yin held about 11.20 million shares, or about 1.79%; the 2025 annual report disclosed that the two largest shareholders held about 14.93% and 10.94%, respectively, and the ownership structure is relatively dispersed. In other words, management credibility comes more from industry reputation, technical route, and long-term execution than from direct economic alignment created by very high ownership as in many family-controlled businesses.
Capital allocation is the issue in AMEC that deserves the closest look and is also most easily covered up by a “good story.” The company's cash mainly goes to three things: R&D, capacity and base expansion, and platform acquisitions/layout. R&D investment in 2025 was about RMB 3.744 billion. In the first half of 2025, the company had disclosed that production and R&D bases of about 140,000 square meters in Nanchang and about 180,000 square meters in Shanghai Lingang had been put into use, and it planned to build new production and R&D bases in Guangzhou Zengcheng and Chengdu High-tech Zone. In addition, the company is advancing a transaction to acquire control of Hangzhou Zhongsi through issuing shares and paying cash. Strategically, these moves all make sense, because semiconductor equipment is a classic reinvestment-driven industry. But for shareholders, the question is whether these investments will turn into per-share intrinsic value in the future, rather than merely producing a larger scale and a better story.
In shareholder returns, the company is more “reinvestment-oriented” and does not rely on high dividends or buybacks to prove capital discipline. Public dividend records show that the company paid RMB 2.0 per 10 shares for the 2023 interim period, RMB 3.0 per 10 shares at year-end 2023 and year-end 2024, and RMB 3.5 per 10 shares at year-end 2025, while also converting capital reserve into 4.9 shares per 10 shares. On Reuters/LSEG's basis, the dividend yield was only about 0.09%. Separately, in May 2026, the company added about 1.9231 million listed shares due to equity-incentive vesting, increasing share capital from 626.9 million shares to 628.8 million shares. After the 4.9-for-10 bonus issue, Reuters/LSEG shows current issued shares under the float basis at about 936.97 million shares. The bonus issue is not economic dilution, but the equity incentive does mean continued small dilution. My conclusion is: the direction of capital allocation is not bad, but constraints on per-share value are not strong enough, and dividends and buybacks are not major highlights. I score “management and capital allocation” at 3.5/5.
Financial Quality and Owner Earnings
First, a note on method. Because SSE PDFs are not stable in search retrieval, the key figures below are mainly cross-checked from three types of sources: Reuters/LSEG structured financial data, search snippets from company preliminary results/quarterly reports/annual reports, and mirrored company announcements. Where an item cannot be stably verified, I explicitly write “additional information needed” rather than forcing in a number.
In terms of growth, AMEC has been very impressive over the past few years. Revenue in 2019 was about RMB 1.947 billion, and net profit attributable to shareholders was about RMB 189 million; in 2020, they were about RMB 2.273 billion and RMB 492 million; in 2021, about RMB 3.108 billion and RMB 1.011 billion; in 2022, about RMB 4.740 billion and RMB 1.170 billion; in 2023, about RMB 6.264 billion and RMB 1.786 billion; in 2024, about RMB 9.065 billion and RMB 1.616 billion; and in 2025, about RMB 12.385 billion and RMB 2.111 billion. On this basis, 2019-2025 revenue CAGR was about 36%, and 2021-2025 revenue CAGR was about 41%. This is an extremely rare high-growth curve.
The other side of the growth curve is that profit quality and cash-flow quality are not as easy as the stock-price narrative suggests. In 2023-2025, on Reuters/LSEG's basis, the company's gross profit was about RMB 2.859 billion, RMB 3.603 billion, and RMB 4.772 billion, respectively, corresponding to gross margins of about 45.6%, 39.8%, and 38.5%. Net margins attributable to shareholders were about 28.5%, 17.8%, and 17.0%. Looking at recurring net profit, which better represents operating reality, 2023 was about RMB 1.19 billion, 2024 about RMB 1.388 billion, and 2025 about RMB 1.550 billion, implying a recurring net margin of only about 12.5% in 2025. In particular, the company disclosed equity investment income of about RMB 607 million included in non-recurring gains and losses in 2025, which means reported profit is not the same as operating cash profit.
The table below summarizes the financial-quality metrics I consider most important. Revenue, gross profit, net profit attributable to shareholders, total assets, total liabilities, and operating cash flow come from Reuters/LSEG; recurring net profit, cash outlays for long-term assets such as fixed assets/intangible assets, and cash related to capitalized development expenditure come from company annual-report/quarterly-report search snippets; gross margin, net margin, debt-to-asset ratio, standard free cash flow, and the “strict owner earnings proxy” are calculated from them.
| Year | Revenue | YoY | Gross margin | Net profit attributable to shareholders | Recurring net profit | Operating cash flow | Standard FCF | Strict OE proxy | Total assets | Total liabilities | Debt-to-asset ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | RMB 6.264 billion | 32.2% | 45.6% | RMB 1.786 billion | About RMB 1.19 billion | -RMB 977 million | -RMB 1.847 billion | Additional information needed | RMB 21.526 billion | RMB 3.699 billion | 17.2% |
| 2024 | RMB 9.065 billion | 44.7% | 39.8% | RMB 1.616 billion | RMB 1.388 billion | RMB 1.458 billion | RMB 563 million | -RMB 281 million | RMB 26.218 billion | RMB 6.481 billion | 24.7% |
| 2025 | RMB 12.385 billion | 36.6% | 38.5% | RMB 2.111 billion | RMB 1.550 billion | RMB 2.295 billion | RMB 1.440 billion | RMB 421 million | RMB 29.846 billion | RMB 7.151 billion | 24.0% |
For long-term investors, three points in this table matter most. First, revenue growth is very strong, but gross margin is declining, which shows the company has not automatically gained stronger and stronger pricing power from domestic substitution, at least not yet. Second, operating cash flow is improving, but free cash flow is not stable: if you treat only cash outlays for fixed assets/intangible assets as capex, then standard FCF did turn positive in 2024 and 2025; but if you also treat “cash paid for projects directly related to development expenditure meeting capitalization conditions” as necessary operating investment, then 2024 was still negative, and 2025 was only RMB 421 million. Third, the balance sheet itself is robust, but that does not automatically mean the equity has a margin of safety, because a solid balance sheet and a cheap share price are different things.
Next, working capital. At the end of 2023, inventory was about RMB 4.26 billion, and contract liabilities were about RMB 770 million. By the end of 2025, sell-side research organized from the annual report showed inventory of about RMB 7.17 billion and contract liabilities of about RMB 3.04 billion. In Q1 2026, contract liabilities fell back to about RMB 2.853 billion, while accounts payable increased from about RMB 1.856 billion at the end of 2025 to about RMB 2.077 billion. This data set sends a typical equipment-company signal: backlog and delivery schedules are heavy, and revenue recognition and cash collection are not naturally smooth. This is not a bad thing, but it reminds you not to evaluate AMEC through the lens of a consumer-goods company.
The complete year-by-year balances of accounts receivable, notes receivable, and contract assets could not be stably extracted under a unified basis from the public snippets directly retrieved this time, so I am not willing to force the numbers. But it can be confirmed that the company applies the lifetime expected credit loss model to notes receivable, accounts receivable, and contract assets in its annual report. Given the extremely high concentration of the top five customers, what needs continuous tracking in the future is not an abstract “bad-debt ratio,” but payment rhythm from major customers, changes in contract assets, and whether revenue recognition and cash collection are synchronized. This area requires supplementary direct annual-report statements for a more rigorous special review.
On ROE, ROA, leverage, and survival capacity, my conclusion is: AMEC is not financially fragile, but it is also not a high-cash-return company. Based on a rough estimate at the end of 2025, ROE was around 9%, and ROA around 7%; Reuters/LSEG's current key metrics page also gives ROE around 9.16%. Total debt at the end of 2025 was about RMB 754 million, while Yahoo Finance's latest key statistics showed total cash of about RMB 8.53 billion, implying net cash of about RMB 7.78 billion. Therefore, net debt/EBITDA is significantly negative, and debt-service risk is very low. The exact interest coverage ratio requires additional information in the structured data currently retrieved, but given the company's net-cash position, financial leverage is not the main issue.
On accounting risk, I have not seen direct evidence of financial fraud in the public materials retrieved, nor have I seen abnormal debt pressure or an unexplained large cash gap. But I would put R&D capitalization on the long-term watchlist. The balance of capitalized development expenditure was about RMB 1.248 billion at the end of 2024 and about RMB 1.535 billion at the end of 2025; by Q1 2026, development expenditure had further reached about RMB 1.902 billion. This does not mean the company has a problem, but it means net profit cannot be directly equated with cash profit freely distributable to shareholders. If commercialization of new products falls short, future amortization and impairment pressure will deserve more attention.
Using an “Owner Earnings” approach to estimate true earning power, I would present two measures. Loose measure: operating cash flow minus cash outlays for fixed assets/intangible assets and other long-term assets, about RMB 1.440 billion in 2025. More conservative measure: further subtract cash related to capitalized development expenditure, about RMB 421 million in 2025. Considering that current heavy R&D and platform expansion include both maintenance and growth components, I think a more prudent “normalized owner earnings range” is roughly RMB 800 million to RMB 1.6 billion per year. This is still materially below the profit level implied by the market's pricing of the equity. At the current market capitalization of about RMB 248.7 billion, AMEC trades at about 160x recurring net profit, 173x loose FCF, and 591x strict OE proxy. From a long-term owner's perspective, that is not an easy number.
Intrinsic Value and Margin of Safety
I will give the conclusion first, then the process. At the current price, AMEC looks more like an expensive option waiting for excellent results to materialize than an asset priced clearly below value. For a relatively conservative investor with a holding period of more than 10 years, I would not define it as a buying opportunity with a margin of safety.
Owner Earnings DCF
This is the hardest part, because the valuation disagreement on AMEC depends almost entirely on how much of today's R&D, capitalized development expenditure, and new-base investment you believe is maintenance spending and how much is growth spending. If we strictly use 2025 cash figures, owner earnings were only about RMB 421 million, making the company obviously very expensive. If you believe most of that spending is front-loaded investment for platform expansion over the next decade, then a higher “normalized starting Owner Earnings” can be justified. I therefore use three scenarios and explicitly state the assumptions. Based on 2025 data, current share count, and conservative treatment of net cash, my estimates are as follows:
| Dimension | Bear | Base | Bull |
|---|---|---|---|
| Starting Owner Earnings assumption | RMB 800 million to RMB 1.0 billion | RMB 1.5 billion to RMB 2.1 billion | RMB 2.5 billion to RMB 3.0 billion |
| Growth rate in the first five years | 20% | 25%–27% | 30% |
| Growth rate in the next five years | 10% | 12% | 15% |
| Discount rate | 11%–12% | 9%–9.5% | 9% |
| Terminal growth rate | 3% | 3.5%–4% | 4% |
| Implied valuation | About RMB 35–60/share | About RMB 95–170/share | About RMB 245–292/share |
The most important message in this table is not a single point estimate. It is that the current market price of RMB 265.47 is already close to, and partly above, the valuation range of the “bull scenario.” What does the bull scenario require? It requires the company's current normalized owner earnings to have already broadly reached or exceeded reported net profit, with the first five years of the next decade maintaining high growth of about 30%, the following five years still achieving high growth of about 15%, a discount rate of only 9%, and terminal growth still at 4%. This is not impossible, but it is no longer a conservative investment assumption. It is an assumption of almost perfect execution.
Relative Valuation
Relative valuation happens to validate the same intuition. As of 2026-06-09, Reuters/LSEG showed AMEC at about P/S 18.95x, adjusted P/E 90.71x, P/B 10.20x, and ROE 9.16%. Compared with its strongest domestic competitor, NAURA Technology Group, at about P/S 10.24x, adjusted P/E 75.98x, and P/B 10.80x, and ACM Research (Shanghai) at about P/S 17.04x, adjusted P/E 87.97x, and P/B 8.64x, with Reuters also showing negative annual free cash flow for ACM Research (Shanghai), AMEC is not valued at a clear discount to peers. It is not cheap on sales and earnings multiples, while NAURA also has broader platform width. If AMEC is assigned a more prudent but still not harsh 12–16x P/S range, the corresponding equity value is about RMB 148.6 billion to RMB 198.2 billion, or roughly RMB 159–211 per share.
Asset and Liquidation Value
This method is usually not the primary valuation method for a high-R&D equipment company, but it is useful for showing “how thick the downside cushion is.” At the end of 2025, on Reuters/LSEG's basis, the company had total assets of about RMB 29.846 billion and total liabilities of about RMB 7.151 billion, corresponding to book shareholders' equity of about RMB 22.695 billion. Based on the current share count, book value per share is only around RMB 24/share. Looking at cash, Yahoo Finance's latest key statistics showed total cash of about RMB 8.53 billion, compared with Reuters/LSEG 2025 year-end total debt of about RMB 754 million, implying net cash of about RMB 7.78 billion, or only about RMB 8/share. This reminds us that asset value provides very little protection for today's share price. Buying AMEC is essentially buying the realization of competitiveness and cash flow over the next decade, not buying assets at a discount.
Combining the three methods, I give the following valuation ranges:
| Valuation Range | My range | Explanation |
|---|---|---|
| Conservative intrinsic value | RMB 25–90/share | Close to the lower bound under strict Owner Earnings and the asset method |
| Fair intrinsic value | RMB 130–210/share | Balances relative valuation and partial Owner Earnings normalization |
| Bull intrinsic value | RMB 240–300/share | Requires long-lasting high growth and near-perfect profit and cash-flow realization |
At the current RMB 265.47/share, AMEC is roughly above the fair value range and close to the middle of the bull value range. For conservative investors, I think the required margin of safety should be at least a 20%–30% discount to the lower bound of fair value, so the ideal buy range is roughly RMB 110–150/share. If you have already held it for a long time and confirm that platform realization is proceeding smoothly, RMB 150–220/share can be understood as a “barely acceptable holding price range.” Above RMB 250/share, I would view it as clearly overvalued.
The margin-of-safety question can also be stated more directly: If AMEC only achieves revenue CAGR of 12%, a net margin of 14%, and an exit valuation of 35x P/E over the next decade, annualized returns from buying today are likely negative or close to zero. If it achieves revenue CAGR of 15%, a net margin of 16%, and an exit valuation of 35x P/E, annualized returns are only in the low single digits. Only under strong assumptions of revenue CAGR of 18%–20%, a net margin of 18%, and an exit valuation still at 40–45x P/E could annualized returns enter the 7%–10% range. For balanced, relatively conservative capital, those odds are not attractive. So the answer is clear: the current price does not provide a sufficient margin of safety.
Risks, Bear Case, and Failure Conditions
AMEC's most important risk is not share-price volatility, but permanent capital loss. The first risk is excessive valuation. Today's share price already discounts very strong growth, very high execution quality, and a long runway dividend. If growth or margins over the next 2–3 years are even merely “not that good,” valuation multiple compression could cause significant capital loss. Based on the current 18.95x P/S and 90.71x adjusted P/E, if the market simply re-rates it to a still not cheap 10–12x P/S or 40–50x recurring earnings range, a 40%–60% share-price drawdown would not be exaggerated.
The second risk is competition and technology-cycle risk. AMEC is already strong in etch, but the industry is not static. SEMI clearly states that important drivers of future foundry/logic equipment demand include advanced nodes, GAA architecture migration, and new device structures. This means industry demand may not disappear, but if AMEC falls behind in key technology generations such as high-selectivity etch, next-generation ICP, and advanced thin films, demand may remain in the industry but not necessarily remain with the company. NAURA's broader platform capability and the deep accumulation of international leaders in certain process steps mean AMEC's moat is not unchallengeable.
The third risk is customer concentration and policy dependence. In 2025, the top five customers contributed 75% of revenue, which binds AMEC's growth to the expansion cycles, yield ramps, capex schedules, and domestic-equipment adoption pace of a small number of major customers. At the same time, Reuters cited people familiar with the matter as saying that newly built Chinese fabs were required to use more than 50% domestic equipment. This is a potential positive for AMEC, but conversely, it also shows that part of the growth logic is strongly policy-driven. If policy support weakens at the margin, local subsidy timing changes, customer expansion is delayed, or budgets shrink, the company's orders and deliveries may come under pressure.
The fourth risk is mismatch between cash flow and accounting measures. Reported profit looked good in 2025, but recurring net profit was only RMB 1.550 billion, and the balance of capitalized development expenditure rose from RMB 1.248 billion at the end of 2024 to RMB 1.535 billion at the end of 2025, then further to about RMB 1.902 billion in Q1 2026. If over the next few years you continue to see “nice net profit, but thin strict Owner Earnings,” that would indicate AMEC may be more suitable as a growth-story stock than as a long-term cash-return asset. This is not saying the company has a problem. It is saying the return logic of your purchase must match the company's real cash economics.
The fifth risk is capital allocation and acquisition integration. The company is clearly in reinvestment mode: R&D, new bases, and platform expansion all require capital. At the same time, the transaction around acquiring control of Hangzhou Zhongsi means there will be new variables in integration, valuation, culture, and execution. For a company that is already very expensive, one capital-allocation mistake in a high-priced acquisition would sharply reduce the market's tolerance.
If I were to write the strongest bear case, I would put it this way: “AMEC is not a bad company. It is a good company with a bad price. The market is pricing it with a near-perfect script: domestic substitution advances steadily, etch share continues to rise, thin-film/EPI/metrology and inspection ramp smoothly, potential acquisitions integrate well, high R&D spending is not wasted, capitalized development expenditure all commercializes successfully, and ten years from now the market is still willing to give it a high valuation multiple. If even two or three of these items fail to happen together, shareholder returns may be very ordinary.” This bear case is not extreme. It is quite powerful within my framework.
What facts would overturn the current “keep watching rather than buy” judgment? I would track the following: First, strict owner earnings improve significantly over the next two to three years and stabilize above RMB 1.5–2.0 billion per year; second, new platforms beyond etch generate substantive revenue and cash flow rather than just R&D stories; third, gross margin and recurring net margin stop declining and even recover, without relying on large non-recurring gains; fourth, customer concentration declines, or at least major-customer expansion becomes more sustainable; fifth, the share price falls back to a more reasonable range and materially improves the odds. Conversely, if the following facts appear, I would admit I was wrong and avoid it more firmly: contract liabilities decline materially, inventory stays high while delivery stalls, gross margin falls below 35%, capitalized development expenditure keeps growing rapidly but new-product commercialization fails, acquisition integration goes poorly, or cash flow remains weaker than profit for a long time.
Comparisons, Checklist, and Final Judgment
First, a horizontal comparison. The valuation and key metrics for AMEC, NAURA, and ACM Research (Shanghai) in the table below come from Reuters/LSEG; the CSI 300 valuation comes from third-party compilations based on China Securities Index data; the China 10-year government bond yield comes from the China bond yield curve/CFETS.
| Object | Current approximate valuation/yield | Implication |
|---|---|---|
| AMEC | P/S 18.95x; adjusted P/E 90.71x; P/B 10.20x; ROE 9.16% | High growth expectations are already heavily priced in |
| NAURA Technology Group | P/S 10.24x; adjusted P/E 75.98x; P/B 10.80x | Broader platform, yet lower valuation |
| ACM Research (Shanghai) | P/S 17.04x; adjusted P/E 87.97x; P/B 8.64x | The industry is generally not cheap, but AMEC has no obvious discount |
| CSI 300 | TTM P/E about 14.23x | Buying AMEC means giving up a lower-valuation index alternative |
| China 10-year government bond | About 1.73%–1.74% | Risk-free yield is low, but AMEC should still require a higher risk premium |
On the question of “is it clearly better than buying the index,” my answer is: not obvious at the current price. The CSI 300's P/E is only a fraction of AMEC's. Even if you acknowledge that the index lacks growth, it wins on cheapness, diversification, and tolerance for error. To prove it deserves to significantly outperform the index, AMEC must continue to deliver above-industry growth and cash realization over the next decade. From today's odds, there is not much room for mistakes. Relative to the 1.73%–1.74% China 10-year government bond yield, AMEC certainly has a higher long-term return ceiling, but that ceiling depends on very strong execution, not on cash flow already in hand. If I could hold only 5 assets, I do not think AMEC has a strong enough claim to enter the portfolio at the current price.
Below is the long-term investment checklist you requested. I use “Pass / Fail / Uncertain” where possible and explain the reason when uncertain.
| Checklist | Conclusion | Explanation |
|---|---|---|
| Can I understand this business? | Pass | The economic logic is understandable, but technical details are complex |
| Does it have long-term stable demand? | Pass | Advanced processes and domestic substitution support long-term demand |
| Does it have a durable moat? | Uncertain | The etch moat is fairly strong, but the platform moat is still being built |
| Does it have pricing power? | Uncertain | It has some bargaining power in critical processes, but customer concentration is a major constraint |
| Can it generate stable free cash flow? | Fail | Cash flow improved in 2023-2025, but the strict measure remains unstable |
| Is its return on capital excellent? | Uncertain | ROE is around 9%, which is not impressive |
| Is management trustworthy? | Pass | Long-term and R&D orientation are relatively clear |
| Is capital allocation rational? | Uncertain | Direction is reasonable, but return verification is still pending |
| Is the balance sheet robust? | Pass | Net cash, low debt, low leverage |
| Is valuation below intrinsic value? | Fail | Current price is above the fair range and close to the bull range |
| Is the margin of safety sufficient? | Fail | The current price leaves little room for error |
| Would I be comfortable holding it long term? | Uncertain | It depends on whether you can continuously track technology and cash flow |
| What key facts would make me sell? | See below | Deterioration in cash flow, gross margin, capitalized R&D, and order quality |
| Am I interested only because of price action or sentiment? | Probably yes | The current price is more easily driven by sector narrative |
Final rating: Watch. One-sentence investment thesis: AMEC is an excellent and highly promising Chinese high-end semiconductor equipment company, but at the current price around RMB 265, the market has already paid too much in advance for a fairly smooth growth script over the next decade.
The core bull reasons are mainly fourfold. First, the industry itself is good enough: SEMI data show the global semiconductor equipment market reached about USD 135.0 billion in 2025 and remains on a growth track in 2026-2027. Second, the core business is strong enough: etch equipment remains a high-barrier core area, and the installed base is already large. Third, new platforms are starting to scale: thin-film equipment has moved from validation to revenue contribution. Fourth, the balance sheet is robust: clear net cash gives the company ample ammunition for continued R&D and expansion.
The core bear reasons are also substantial. First, the current valuation is too high and already approaches bull-scenario pricing. Second, truly distributable cash flow is far less impressive than reported profit. Third, customer concentration is high, policy variables are strong, and technology routes iterate quickly. Fourth, capitalized development expenditure and platform expansion mean future amortization/impairment and execution risk cannot be ignored.
If the key assumptions fail, the investment logic weakens. At minimum, I think the following must be satisfied: etch equipment continues to scale in advanced logic and memory critical steps; thin-film, EPI, metrology/inspection, and potential wet-process/CMP platforms truly form cash returns; capitalized R&D projects convert at high quality rather than accumulating accounting assets; and during the high-growth phase, the company can gradually raise strict owner earnings closer to recurring profit.
Fair buy price range: RMB 110–150/share. This range roughly corresponds to the requirement of retaining a 20%–30% margin of safety below the lower bound of fair intrinsic value, and better fits your “balanced, relatively conservative” risk preference. Acceptable holding price range: RMB 150–220/share. Clearly overvalued range: above RMB 250/share. Based on the 2026-06-09 price of about RMB 265.47, I tend to place it on the “clearly overvalued” side.
Target holding period: more than 10 years, but only if you are willing to track fundamentals frequently. This is not a company you buy and put in a drawer for ten years without looking. It is better suited to a “long-term holding plus continuous recalculation” framework.
Expected annualized return under relatively prudent ten-year scenarios would be as follows: The bear case is about -3% to 0%; the base case about 1% to 4%; and the bull case about 7% to 10%. In other words, buying at the current price becomes attractive only if the company maintains very strong growth over the next decade and the market remains willing to assign a high valuation. For conservative capital, the odds are not thick enough.
The maximum loss risk is not business failure, but “excellent company, valuation reversion.” If revenue and profit growth disappoint market expectations over the next 3–5 years while valuation compresses from nearly 19x P/S to 10–12x, or from nearly 90x adjusted P/E to 40–50x, a 40%–60% permanent capital loss in the share price would not be surprising. If technology misjudgment, acquisition mistakes, or policy/order headwinds are added, the loss could be larger.
Key indicators to track going forward should include at least these eight items: Revenue growth; etch equipment revenue mix and growth; revenue from new platforms such as thin-film/EPI/metrology and inspection; gross margin and recurring net margin; operating cash flow and strict Owner Earnings; the balance of capitalized development expenditure and its share of revenue; changes in contract liabilities and inventory; top-five customer concentration and breakthroughs with new key customers.
Signals that should trigger reassessment include: Gross margin declining clearly for two to three consecutive reporting periods; contract liabilities weakening while inventory keeps rising; capitalized R&D continuing to grow rapidly while new products fail to convert into revenue; etch growth significantly lagging the industry and core peers; integration or realization problems after the Hangzhou Zhongsi acquisition; and strict Owner Earnings failing to rise for a long time.
Final recommendation: If your goal is to own one of the few Chinese semiconductor equipment companies with genuine global competitive potential, AMEC deserves long-term tracking and even deep research for a future cheaper opportunity. But if your goal is to buy a good business today at a reasonable price that is likely to make real money ten years from now, I would stay disciplined: first admit it is a good company, then admit it may not be a good price right now. For conservative capital, the most rational action is not to chase, but to wait.
This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.
Full report
Sign in to read the full report
Sign up free to unlock the full text, the Baillie growth scorecard, and full-text search.
Log in / Sign up free